Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.57 |
| ▸ | NOS1 | P29475 | 1/20 | 0.57 |
| ▸ | NOS2 | P35228 | 1/20 | 0.57 |
| ▸ | RIOK2 | Q9BVS4 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NR3C2 | P08235 | 11/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.39 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31119421 | 1.00 | NOS3 (0.57) | NOS3NOS1NOS2RIOK2PKM | |
| SCHEMBL10238962 | 0.85 | NR3C2 (0.44) | NOS3NOS1NOS2KDM4ENR3C2 | |
| SCHEMBL11015263 | 0.82 | MME (0.43) | NOS3NOS1NOS2KDM4ENR3C2 | |
| SCHEMBL31325755 | 0.82 | NOS2 (0.53) | NOS3NOS1NOS2RIOK2PKM | |
| SCHEMBL2056325 | 0.82 | NOS2 (0.53) | NOS3NOS1NOS2RIOK2PKM | |
| SCHEMBL5070476 | 0.80 | RECQL (0.52) | NR3C2 | |
| SCHEMBL10444896 | 0.80 | NOS2 (0.52) | NOS3NOS1NOS2RIOK2PKM | |
| SCHEMBL12883355 | 0.77 | NOS2 (0.48) | NOS3NOS1NOS2RIOK2PKM | |
| SCHEMBL14270718 | 0.77 | NOS3 (0.48) | NOS3NOS1NOS2RIOK2PKM | |
| SCHEMBL13950725 | 0.77 | RIOK2 (0.49) | NOS3NOS1NOS2RIOK2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9359329-B2 | Derivatives of 2-pyridin-2-yl-pyrazol-3(2H)-one, preparation and therapeutic use thereof | SANOFI (FR) | 2016-06-07 | — | — | US | disclosed |
| US-20160137627-A9 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2016-05-19 | — | — | US | disclosed |
| US-20140194470-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2014-07-10 | — | — | US | disclosed |
| US-8697731-B2 | Derivatives of 2-pyridin-2-yl-pyrazol-3(2H)-one, preparation and therapeutic use thereof | SANOFI (FR) | 2014-04-15 | — | — | US | disclosed |
| CN-101613344-B | Fluorescent probe for selectively detecting zinc ions in cells and synthetic method and application thereof | CHINESE ACAD TECH INST PHYSICS | 2012-09-12 | — | — | CN | disclosed |
| EP-2086973-B1 | IMIDAZO- AND TRIAZOLO-PYRIDINE COMPOUNDS AND METHODS OF USE THEROF | AMGEN INC (US) | 2012-01-25 | — | — | EP | disclosed |
| CN-102333776-A | Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof | SANOFI AVENTIS | 2012-01-25 | — | — | CN | disclosed |
| US-20110301148-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-12-08 | — | — | US | disclosed |
| EP-2382215-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2011-11-02 | — | — | EP | disclosed |
| WO-2010076525-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | WO | disclosed |
| WO-2010050445-A1 | BICYCLIC COMPOUND | 武田薬品工業株式会社 (JP) | 2010-05-06 | — | — | WO | disclosed |
| CN-101613344-A | Fluorescent probe for selectively detecting zinc ions in cells and synthetic method and application thereof | CHINESE ACAD TECH INST PHYSICS | 2009-12-30 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137627-A9 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF | NR3C2, NR3C1, NR5A2 | NOS3 561/4885NOS1 1147/4885NOS2 1069/4885 |
| US-20140194470-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF | NR3C2, NR3C1, NR5A2 | NOS3 561/4885NOS1 1147/4885NOS2 1069/4885 |
| US-20110301148-A1 | DERIVATIVES OF 2-PYRIDIN-2-YL-PYRAZOL-3(2H)-ONE, PREPARATION AND THERAPEUTIC USE THEREOF | NR3C2, NR3C1, NR5A2 | NOS3 561/4885NOS1 1147/4885NOS2 1069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.